209 related articles for article (PubMed ID: 22150825)
61. Randomized phase II trials with a prospective control.
Jung SH
Stat Med; 2008 Feb; 27(4):568-83. PubMed ID: 17573688
[TBL] [Abstract][Full Text] [Related]
62. Making the investigational oncology pipeline more efficient and effective: are we headed in the right direction?
LoRusso PM; Anderson AB; Boerner SA; Averbuch SD
Clin Cancer Res; 2010 Dec; 16(24):5956-62. PubMed ID: 21169248
[TBL] [Abstract][Full Text] [Related]
63. One- and two-stage designs for phase II window studies.
Chang MN; Devidas M; Anderson J
Stat Med; 2007 Jun; 26(13):2604-14. PubMed ID: 17211853
[TBL] [Abstract][Full Text] [Related]
64. Statistics in oncology.
Land SR; Abrams J; Buyse M; Chappell RJ
J Clin Oncol; 2008 Aug; 26(22):3668. PubMed ID: 18669450
[No Abstract] [Full Text] [Related]
65. Point estimation and p-values in phase II adaptive two-stage designs with a binary endpoint.
Kunzmann K; Kieser M
Stat Med; 2017 Mar; 36(6):971-984. PubMed ID: 28028823
[TBL] [Abstract][Full Text] [Related]
66. Bayesian dose-finding in phase I/II clinical trials using toxicity and efficacy odds ratios.
Yin G; Li Y; Ji Y
Biometrics; 2006 Sep; 62(3):777-84. PubMed ID: 16984320
[TBL] [Abstract][Full Text] [Related]
67. Comparing an experimental agent to a standard agent: relative merits of a one-arm or randomized two-arm Phase II design.
Taylor JM; Braun TM; Li Z
Clin Trials; 2006; 3(4):335-48. PubMed ID: 17060208
[TBL] [Abstract][Full Text] [Related]
68. Statistical inference for extended or shortened phase II studies based on Simon's two-stage designs.
Zhao J; Yu M; Feng XP
BMC Med Res Methodol; 2015 Jun; 15():48. PubMed ID: 26048655
[TBL] [Abstract][Full Text] [Related]
69. Phase II trials powered to detect tumor subtypes.
Roberts JD; Ramakrishnan V
Clin Cancer Res; 2011 Sep; 17(17):5538-45. PubMed ID: 21737510
[TBL] [Abstract][Full Text] [Related]
70. Improving the decision to pursue a phase 3 clinical trial by adjusting for patient-specific factors in evaluating phase 2 treatment efficacy data.
Heller G; Kattan MW; Scher HI
Med Decis Making; 2007; 27(4):380-6. PubMed ID: 17761958
[TBL] [Abstract][Full Text] [Related]
71. An adaptive two-stage design with treatment selection using the conditional error function approach.
Wang J
Biom J; 2006 Aug; 48(4):679-89. PubMed ID: 16972720
[TBL] [Abstract][Full Text] [Related]
72. Optimal two-stage designs for single-arm phase II oncology trials with two binary endpoints.
Kunz CU; Kieser M
Methods Inf Med; 2011; 50(4):372-7. PubMed ID: 21057719
[TBL] [Abstract][Full Text] [Related]
73. A new statistical decision rule for single-arm phase II oncology trials.
Chen Y; Chen Z; Mori M
Stat Methods Med Res; 2016 Feb; 25(1):118-32. PubMed ID: 22461073
[TBL] [Abstract][Full Text] [Related]
74. Design of Phase II cancer trials evaluating survival probabilities.
Case LD; Morgan TM
BMC Med Res Methodol; 2003 Apr; 3():6. PubMed ID: 12697051
[TBL] [Abstract][Full Text] [Related]
75. Advantages of multi-arm non-randomised sequentially allocated cohort designs for Phase II oncology trials.
Mossop H; Grayling MJ; Gallagher FA; Welsh SJ; Stewart GD; Wason JMS
Br J Cancer; 2022 Feb; 126(2):204-210. PubMed ID: 34750494
[TBL] [Abstract][Full Text] [Related]
76. Flexible designs for phase II comparative clinical trials involving two response variables.
Bersimis S; Sachlas A; Papaioannou T
Stat Med; 2015 Jan; 34(2):197-214. PubMed ID: 25274584
[TBL] [Abstract][Full Text] [Related]
77. A review of statistical designs for improving the efficiency of phase II studies in oncology.
Wason JM; Jaki T
Stat Methods Med Res; 2016 Jun; 25(3):1010-21. PubMed ID: 26031358
[TBL] [Abstract][Full Text] [Related]
78. Single-arm phase IIA clinical trials with go/no-go decisions.
Zhong B
Contemp Clin Trials; 2012 Nov; 33(6):1272-9. PubMed ID: 22796490
[TBL] [Abstract][Full Text] [Related]
79. Two-stage phase II oncology designs using short-term endpoints for early stopping.
Kunz CU; Wason JM; Kieser M
Stat Methods Med Res; 2017 Aug; 26(4):1671-1683. PubMed ID: 26037529
[TBL] [Abstract][Full Text] [Related]
80. A literature review of applied adaptive design methodology within the field of oncology in randomised controlled trials and a proposed extension to the CONSORT guidelines.
Mistry P; Dunn JA; Marshall A
BMC Med Res Methodol; 2017 Jul; 17(1):108. PubMed ID: 28720094
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
